Lipocine (LPCN) Status Update summary

Postpartum depression landscape and unmet needs

• PPD affects up to 25% of women globally, with significant maternal and child health and economic impacts, costing $14.2 billion annually in the U.S. alone.

• Updated clinical guidelines now recommend routine screening for depression and anxiety during and after pregnancy, increasing diagnosis and treatment rates.

• Traditional SSRIs/SNRIs are first-line but have slow onset, low remission rates, and burdensome side effects, leading to poor adherence and incomplete treatment.

• Neuroactive steroid antidepressants, such as brexanolone and zuranolone, offer rapid symptom relief and shorter treatment courses, with fewer chronic side effects.

• Breastfeeding safety is a key concern; both brexanolone and zuranolone show low infant exposure, but shorter treatment duration is preferable for lactating women.

LPCN 1154 product profile and clinical development

• LPCN 1154 is an oral bioidentical brexanolone designed for a 48-hour outpatient regimen, aiming to provide rapid relief for PPD without hospital stays.

• The proprietary oral delivery technology enables effective absorption, matching IV brexanolone exposure and eliminating the need for titration.

• Phase I/II studies showed LPCN 1154 is well tolerated, with only mild to moderate adverse events and no serious CNS depressant effects.

• The ongoing phase III trial is a randomized, placebo-controlled study in women with severe PPD, with primary endpoint at 60 hours and follow-up to 30 days.

• FDA has agreed that a single positive phase III study, supported by dosing confirmation data, will suffice for NDA submission, targeted for mid-2026.

Market potential, prescribing dynamics, and future outlook

• There is a significant unmet need for rapid, effective, and convenient PPD treatments, with growing awareness and diagnosis rates.

• Prescribing is currently split between OB/GYNs and psychiatrists, with OB/GYNs increasingly initiating treatment due to frequent patient contact.

• Short-duration, oral neuroactive steroids fit well into OB/GYN practice workflows and may improve adherence and outcomes.

• The 48-hour regimen of LPCN 1154 could address breastfeeding concerns and improve patient acceptance compared to longer treatments.

• If approved, LPCN 1154 could become a new standard of care for PPD and may have potential in other depressive disorders, including treatment-resistant cases.